BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Targeted therapy with small molecule inhibitors, such as tyrosine kinase inhibitors (TKIs) for t(9;22) BCR-ABL gene fusion for Chronic Myeloid Leukemia (CML) or all-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APML), have already proven to be successful [32].